Literature DB >> 3488911

Immunity to lymphocytic choriomeningitis virus in B cell-depleted mice: evidence for B cell and antibody-independent protection by memory T cells.

A Cerny, A W Huegin, S Sutter, H Bazin, H H Hengartner, R M Zinkernagel.   

Abstract

Immunity against lymphocytic choriomeningitis virus (LCMV) in anti-IgM-treated B cell-depleted mice was evaluated. We found that the following immune phenomena were independent of antibodies: the generation of virus-specific cytotoxic T cells; the footpad swelling response against locally injected LCMV; natural killer cell activity basic levels or after LCMV or poly(I) X poly(C) stimulation; immunopathologically mediated LCM after primary intracerebral inoculation; immunological memory in LCMV-immune mice assessed by immune protection against LCM after intracerebrally injected virus or as resistance against the local footpad swelling response to LCMV. This study demonstrates that humoral immunity plays no crucial role in immune protection and immunopathology in murine LCMV infection and suggests that protective memory T cell function is B cell and antibody independent.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3488911     DOI: 10.1002/eji.1830160807

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  11 in total

1.  Antigen-specific CD4 T-cell help rescues exhausted CD8 T cells during chronic viral infection.

Authors:  Rachael D Aubert; Alice O Kamphorst; Surojit Sarkar; Vaiva Vezys; Sang-Jun Ha; Daniel L Barber; Lilin Ye; Arlene H Sharpe; Gordon J Freeman; Rafi Ahmed
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-12       Impact factor: 11.205

2.  Antiviral antibodies attenuate T-cell-mediated immunopathology following acute lymphocytic choriomeningitis virus infection.

Authors:  K E Wright; M J Buchmeier
Journal:  J Virol       Date:  1991-06       Impact factor: 5.103

3.  Molecularly engineered vaccine which expresses an immunodominant T-cell epitope induces cytotoxic T lymphocytes that confer protection from lethal virus infection.

Authors:  L S Klavinskis; J L Whitton; M B Oldstone
Journal:  J Virol       Date:  1989-10       Impact factor: 5.103

4.  Activated B cells can deliver help for the in vitro generation of antiviral cytotoxic T cells.

Authors:  Y Liu; A Müllbacher
Journal:  Proc Natl Acad Sci U S A       Date:  1989-06       Impact factor: 11.205

5.  Enhanced virus clearance by early inducible lymphocytic choriomeningitis virus-neutralizing antibodies in immunoglobulin-transgenic mice.

Authors:  P Seiler; U Kalinke; T Rülicke; E M Bucher; C Böse; R M Zinkernagel; H Hengartner
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

6.  The complementary roles of cellular and humoral immunity in resistance to re-infection with LCM virus.

Authors:  A R Thomsen; O Marker
Journal:  Immunology       Date:  1988-09       Impact factor: 7.397

7.  Evidence for an underlying CD4 helper and CD8 T-cell defect in B-cell-deficient mice: failure to clear persistent virus infection after adoptive immunotherapy with virus-specific memory cells from muMT/muMT mice.

Authors:  D Homann; A Tishon; D P Berger; W O Weigle; M G von Herrath; M B Oldstone
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

8.  Clearance of lymphocytic choriomeningitis virus in antibody- and B-cell-deprived mice.

Authors:  A Cerny; S Sutter; H Bazin; H Hengartner; R M Zinkernagel
Journal:  J Virol       Date:  1988-05       Impact factor: 5.103

9.  Slc15a4, a gene required for pDC sensing of TLR ligands, is required to control persistent viral infection.

Authors:  Amanda L Blasius; Philippe Krebs; Brian M Sullivan; Michael B Oldstone; Daniel L Popkin
Journal:  PLoS Pathog       Date:  2012-09-13       Impact factor: 6.823

10.  CD40-CD40 ligand interactions are critical in T-B cooperation but not for other anti-viral CD4+ T cell functions.

Authors:  A Oxenius; K A Campbell; C R Maliszewski; T Kishimoto; H Kikutani; H Hengartner; R M Zinkernagel; M F Bachmann
Journal:  J Exp Med       Date:  1996-05-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.